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Objective: To investigate the role in bipolar disorder of the C9ORF72
hexanucleotide repeat expansion responsible for frontotemporal lobe
dementia and amyotrophic lateral sclerosis.
Methods: Eighty-nine subjects from a previously described panel of
individuals with bipolar disorder ascertained for genetic studies were
screened to detect expansion of the C9ORF72 repeat. One two-
generation family with bipolar disorder and an expanded repeat was
characterized in depth using molecular diagnostics, imaging,
histopathology, and neurological and neuropsychological evaluation.
Results: One proband, with the typical clinical presentation of bipolar
disorder, carried an expanded C9ORF72 allele of heterogeneous length
between 14 and 20 kilobases (kb) as assessed by Southern blot. The
expanded allele was inherited from a parent with atypical, late onset
clinical features of bipolar disorder, who subsequently progressed to
frontotemporal lobe dementia. The expansion in peripheral blood of the
parent ranged from 8.5 to 20 kb. Cultured lymphoblastoid cells from this
parent exhibited a homogeneous expansion of only 8.5 kb.
Conclusions: The disease course in the two generations described here
demonstrates that expansion of the C9ORF72 may be associated with a
form of bipolar disorder that presents clinically with classic
phenomenology and progression to neurodegenerative disease. The
frequency in our bipolar disorder cohort was only 1%, indicating that
C9ORF72 is not a major contributor to bipolar disorder. DNA from
cultured cells may be biased towards shorter repeats and
nonrepresentative of the endogenous C9ORF72 expansion.
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Expansion of the GGGGCC hexanucleotide within
the C9ORF72 gene to several thousand tandem
repeats results in frontotemporal lobe dementia
(FTD) and amyotrophic lateral sclerosis (ALS),
referred to as C9ALSFTD (1–3). C9ORF72 expan-
sions are responsible for approximately 40% of
familial ALS, 7% of sporadic ALS, and 25% of
familial FTD in European populations (4, 5). The
clinical heterogeneity caused by the C9ORF72
expansion extends to corticobasal and ataxia syn-
dromes (6). More than 40% of patients with
C9ALSFTD present with psychiatric disorders
(7–9).
Population studies of several thousand individu-
als described repeat lengths below 30 in unaﬀected
individuals. The frequency of expanded alleles in
unaﬀected individuals was 3/856 (0.3%) in one
study (4) and 5/2585 (0.2%) in another (5). South-
ern blot analysis of the expanded C9ORF72 repeat
reveals a heterogeneous distribution of expansion
length with a smeared appearance indicative of
somatic instability (10). Intergenerational repeat
326
Bipolar Disorders 2013: 15: 326–332 © 2013 John Wiley and Sons A/S
Published by Blackwell Publishing Ltd.
BIPOLAR DISORDERS
instability and genetic anticipation are characteris-
tic of other repeat expansion disorders (11) and
may occur in C9ALSFTD (2). The role of
C9ORF72 in bipolar disease has not previously
been examined. Here, we describe the results of a
small genetic screen. We have characterized a small
family with bipolar disorder with apparent
intergenerational expansion of the C9ORF72
repeat length and anticipation in the onset of
psychopathology.
Materials and methods
Clinical samples
A panel of individuals with bipolar disorder, ascer-
tained for genetics studies, was assessed clinically
and neuropsychologically as previously described
(12). Screening for the expansion in C9ORF72 was
carried out based on the reports of a high fre-
quency of psychiatric disturbances in individuals
with expansions (7). The University of Michigan
Institutional Review Board (Ann Arbor, MI,
USA) approved the use of these samples for
genetic studies of bipolar disorder.
Polymerase chain reaction (PCR) assays
Repeat-primed PCR was carried out as described
(1) with two modiﬁcations: (i) 1.6 M betaine
(Sigma Chemicals, St. Louis, MO, USA) (13) was
freshly dissolved and added to each reaction imme-
diately before PCR; and (ii) touch-down PCR was
followed by an additional 27 cycles at 97°C
for 35 sec, 54.5°C for 35 sec, and 68°C for
3 min + 20 sec per cycle, terminating at 68°C for
10 min. Short alleles (1–10 repeats) were ampliﬁed
with forward primer F1 (5 CCG CAG CCT GTA
GCA AGC) located upstream of the repeat
(Fig. 1A) and reverse primer FAM-R1 from the
repeat-primed assay. Fragment sizes were deter-
mined on an ABI 3730 Sequencer. Additional
details are provided in the Supplementary materi-
als.
Southern blot
The 241-base pair (bp) hybridization probe (3)
located upstream of C9ORF72 was ampliﬁed from
genomic DNA, gel puriﬁed, doubly radiolabeled
with 32P-dCTP plus 32P-dATP (Perkin Elmer, Shel-
ton, CT, USA) using the Prime-a Gene Labeling
System (Promega, Madison, WI, USA), and sepa-
rated from unincorporated nucleotides by centrifu-
gation through a Sephadex-G50 column. A sample
of 10 lg of genomic DNA was digested overnight
with XbaI in the presence of 4 mM spermidine.
Restriction fragments were separated by electro-
phoresis on 0.8% agarose gels with 19 tris-borate-
EDTA buﬀer and transferred to Zetaprobe GT ﬁl-
ters (BioRad Labs, Hercules, CA, USA). Hybrid-
ization with the radiolabeled probe was carried out
in 0.5 M sodium phosphate, 7% sodium dodecyl
sulfate (SDS), pH 7.2 at 65°C overnight. Filters
were washed at 65°C for 15 min twice in solutions
containing 0.1% SDS: 29 saline–sodium citrate
(SSC), 19 SSC, 0.29 SSC, and 0.19 SSC. Bio-
Max-MS ﬁlm (Kodak, Rochester, NY, USA) was
exposed with an intensifying screen at 80°C for
two days. The use of double-labeled probes
improved the sensitivity of the assay.
Immunohistochemistry
Formalin-ﬁxed, paraﬃn embedded sections were
prepared from the middle frontal gyrus, anterior
cingulate gyrus, insular cortex, superior and mid-
dle temporal lobes, inferior parietal cortex, visual
cortex, thalamus and subthalamic nucleus, amyg-
dala, nucleus basalis, hippocampus at the level of
the lateral geniculate nucleus, midbrain at the level
of the red nucleus, pons, medulla oblongata, cere-
bellar folia, and dentate nucleus. Sections were
stained by hematoxylin and eosin, and selected sec-
tions were stained by Bielschowsky silver stain and
by the immunoperoxidase method using a Ventana
automated stainer. Primary antibodies were to glial
ﬁbrillary acidic protein (#20334; DAKO, Carpin-
teria, CA, USA), tau (AT8; Fisher, Pittsburgh,
PA, USA), transactive response DNA-binding
protein 43 (#10782-2-AP; Proteintech Group, Chi-
cago, IL, USA), ubiquitin (UB1; Chemicon, Teme-
cula, CA, USA), b-amyloid (6F-3D; Leica, Buﬀalo
Grove, IL, USA) and a-synuclein (LB509; Invitro-
gen, Carlsbad, CA, USA).
Results
Screen for C9ORF72 expansion in a bipolar disorder
cohort
Eighty-nine DNA samples were selected from a
previously described panel of individuals with
bipolar disorder ascertained for genetic studies
(12). The selected samples were enriched for early
onset and neurocognitive abnormalities. Screening
was carried out by repeat-primed PCR. Three indi-
viduals who were homozygous for a short allele of
C9ORF72, and six individuals with unclear PCR
results, were further tested by PCR with ﬂanking
markers as described below. One patient with an
expanded allele of C9ORF72 is characterized here.
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Clinical features
The family is represented in Figure 1A and is of
Northern European ancestry. The 35-year-old
bipolar proband has the typical clinical pattern
of a bipolar disorder and was diagnosed follow-
ing hospitalization due to an acute manic epi-
sode at 25 years of age. The disorder is
successfully managed with lithium and an anti-
depressant. Current assessment was carried out
using the Diagnostic Interview for Genetic
Studies (DIGS) with DSM-IV criteria (12).
Neuropsychiatric testing reported normal execu-
tive and memory ability, with evidence, discern-
ible only by laboratory-based testing, of slightly
disrupted ﬁne motor functioning (Supplementary
Fig. 1). Additional clinical description is provided
in the Supplementary information.
The proband’s unaﬀected parent has good men-
tal health. The aﬀected parent has a history of hos-
pitalization for bipolar disorder beginning at age
62. This individual has an atypical clinical pattern
that includes many attributes of mood irregulari-
ties that are common within the bipolar spectrum
(14) (detailed in the Supplementary information).
FTD was subsequently diagnosed after the devel-
opment of apathy, progressive language dysfunc-
tion, progressive memory impairment, and gait
disorder. Neurological evaluation at age 66
reported parkinsonian features. The Mini-Mental
State Examination score was 19. Evaluation with
the National Alzheimer Coordinating Center Uni-
form Data Set battery revealed impairments of
attention, executive function, verbal ﬂuency, and
memory (Clinical Dementia Rating sum of boxes
score = 11.5). Positron emission tomography
imaging with the dopamine terminal ligand [11C]
3-alkyl-dihydrotetrabenazine (DTBZ) and the
amyloid ligand [11C]PiB revealed a mild reduction
in striatal dopamine terminals and no evidence of
neocortical Ab amyloid deposition (Fig. 1B) (14).
Magnetic resonance imaging revealed modest
anterior temporal atrophy. The aﬀected parent’s
condition progressed to death at age 69. At
autopsy, the brain weighed 1210 g and showed
mild-to-moderate frontal and temporal lobe atro-
phy. Microscopic evaluation revealed ﬁndings of
both argyrophilic grain disease and Alzheimer’s
disease. Alzheimer’s disease neuropathological
changes (A1, B1, C2) (Fig. 1C, left panel) were low
Fig. 1. Clinical features of the family. (A) Pedigree demonstrating inheritance of bipolar disorder (solid circle) by the proband
(arrow). Frontotemporal lobe dementia was diagnosed in the deceased parent. Genotypes represent hexanucleotide repeat numbers
based on data in Figure 2. (B) Positron emission tomography imaging of the aﬀected parent. Dopamine terminal tracer [11C] 3-alkyl-
dihydrotetrabenazine (DTBZ) binding (top row) is modestly reduced, inconsistent with Lewy body dementia; [11C]PiB binding (bot-
tom row) exhibits a subcortical white matter distribution without the prominent neocortical labeling seen in Alzheimer’s disease and
some cases of Lewy body dementia (14). (C) Histopathology of the aﬀected parent. Left panel: Ab stain highlights neuritic plaques
and amyloid deposition in a small vessel in the parietal cortex (2009). Middle panel: Tau pathology in the entorhinal cortex (AT8
stain, 1009). Right panel: Ubiquitin-positive, tau-, transactive response DNA-binding protein 43-, and a-synuclein-negative cyto-
plasmic inclusions in dentate gyrus (4009).
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level (15), and were accompanied by the presence
of marked tau pathology in the anteromedial tem-
poral lobe (Fig. 1C, middle panel). Although no
TDP-43 inclusions were identiﬁed, neurons in the
frontal and temporal cortex and dentate gyrus con-
tained ubiquitinated cytoplasmic aggregates
(Fig. 1C, right panel).
C9ORF72 repeat detection
The PCR primers and hybridization probe used
for molecular analysis are shown in Figure 2A.
Repeat-primed PCR of genomic DNA revealed
the saw-tooth pattern of products indicative of
an expanded repeat in genomic DNA from the
A
B
C
D
Fig. 2. Molecular characterization of C9ORF72 in family members. (A) Noncoding exons 1a and 1b of C9ORF72 indicating loca-
tions of PCR primers and Southern blot probe. The 716 bp region shown corresponds to chromosome 9p21 from 27573248 bp (at
right) to 27753964 bp (at left) (GRCh37/hg19). The position of the anchor probe sequence at the 50 end of primer F1 is marked ‘a’.
(B) Repeat-primed polymerase chain reaction (PCR) using primers F1, FAM-R1, and a, detected the saw-tooth pattern indicative of
an expanded hexanucleotide repeat in the proband and aﬀected parent. The sharp drop-oﬀ of peak height, characteristic of short
alleles, in seen in the unaﬀected parent. (C) Ampliﬁcation of the short hexanucleotide repeat alleles using PCR primers F2 and
FAM-R1 reveals two diﬀerent short alleles in the unaﬀected parent and a single short allele in the aﬀected parent and proband. (D)
Southern blot of genomic DNA from peripheral blood (lanes 1–3) demonstrates expanded alleles of 14–20 kb in the proband and 8.5
–20 kb in the aﬀected parent. Lymphoblastoid cells from the aﬀected parent exhibit shorter repeat lengths. A gel containing radiola-
beled molecular weight standards is presented in Supplementary Figure 2. Aﬀ = aﬀected parent; B = peripheral blood; bp = base pair;
L = cultured lymphoblastoid cells; Pr = proband; Un = unaﬀected parent.
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proband and the aﬀected parent (Fig. 1B). The
unaﬀected parent’s ampliﬁcation products dem-
onstrated a sharp drop-oﬀ in length consistent
with nonexpanded alleles. This was conﬁrmed by
ampliﬁcation of two short alleles of 306 and
363 bp from the unaﬀected parent, correspond-
ing to one and ten hexanucleotide copies, using
the ﬂanking markers F2 and FAM-R1 (Fig. 2C).
The proband inherited the one-copy allele from
the unaﬀected parent. The aﬀected parent con-
tains a single short allele that was not inherited
by the proband. (The presence of the single
short allele is consistent either with homozygos-
ity or with the presence of a second allele that
is expanded and not detectable with these
primers.)
Length of C9ORF72 expanded repeats
Southern blot analysis of genomic DNA isolated
from peripheral blood revealed expanded hexanu-
cleotide repeat alleles in the proband and the
aﬀected parent (Fig. 2D, lanes 1–3). The 2.3 and
2.4 kb unexpanded alleles in the unaﬀected par-
ent are also visible on short exposure (Supplemen-
tary Fig. 2). The proband carries a short allele of
2.3 kb and a heterogeneous expanded allele with
average length of ~18 kb, which corresponds to
~2600 hexanucleotide copies. Size heterogeneity is
typical for C9ORF72 expansions and is thought
to reﬂect somatic instability of the expanded
repeat. The aﬀected parent also carries a hetero-
geneous expanded allele with a broader size dis-
tribution extending from 8.5 to 20 kb, with
predominance of shorter expansions. Comparison
of the size distribution of expansions between
proband and aﬀected parent demonstrates a
greater representation of longer expansions in the
proband.
Expansion length in cultured lymphoblastoid cells
The most commonly studied source of genomic
DNA for Southern blots of the C9ORF72
expansion is cultured lymphoblast cell lines.
However, comparison of blood and cultured
lymphoblasts from the aﬀected parent revealed a
large diﬀerence (Fig. 2D, lanes 3 and 4). In con-
trast with the broad size distribution in genomic
DNA from whole blood, the lymphoblast cul-
tures are greatly enriched for the short, 8.5 kb
expansion length. The data suggest that there
may be selection during culture for cells contain-
ing short repeats, and indicate that repeat
lengths in lymphoblast DNA may be of limited
diagnostic value.
Discussion
We describe an expanded C9ORF72 repeat in a
family with bipolar disorder and FTD. During
intergenerational transmission from an aﬀected
parent, there was an apparent increase in the aver-
age length of the repeat. This aﬀected parent had
FTD that was initially diagnosed as late-onset
bipolar disease. The parent exhibited a broad dis-
tribution of repeat length between 8.5 and 20 kb,
whereas the proband with early onset carried a
longer distribution between 14 and 20 kb. The ini-
tial presentation in both generations is bipolar dis-
order, suggesting an etiological relationship with
the C9ORF72 repeat expansion. Published exam-
ples of individuals with bipolar disorder who later
developed FTD have not included genetic charac-
terization (16, 17). Intergenerational expansion of
repeated elements in other genes is associated with
genetic anticipation and increased disease severity
in successive generations (11). We previously pre-
sented evidence of clinical anticipation in bipolar
disorder (18). In the currently studied family, there
appears to be a relationship between the age of
onset and average repeat length, suggestive of
genetic anticipation. The proband has typical bipo-
lar phenomenology with ﬁne motor abnormalities
discernible only in the laboratory. This raises ques-
tions regarding the contribution of the C9ORF72
expansion to phenotypic heterogeneity within
bipolar disorder and the relationship between ﬁne
motor dysfunction, mood disorder, the progres-
sion of neurodegenerative disorders, and genetic
anticipation.
The most easily accessed and commonly used
source of genomic DNA for Southern blots of
C9ORF72 is lymphoblastoid cell lines. We found a
signiﬁcant diﬀerence between the expansion proﬁle
in DNA from peripheral blood and lymphoblasts
cultured from the same sample. Shorter expansions
may confer a growth advantage during culture, as
has been demonstrated in myotonic dystrophy,
where the somatic instability of a CTG repeat
expansion in tissues is poorly represented in lym-
phoblastoid cell lines (19, 20). There is likely to be
a complex relationship between the length of the
C9ORF72 expansion observed in the laboratory
and the clinical features of the patient, due to con-
founding factors that include age and tissue source,
somatic instability, and cell growth conditions. It
seems increasingly likely that the degree of expan-
sion in accessible peripheral tissues may not reﬂect
the genetic pathology present in the brain and
nervous system.
Increased size distribution of the C9ORF72
repeat with transmission from an aﬀected parent
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was recently described in an FTD family that
included two aﬀected siblings with diﬀerent repeat
proﬁles in peripheral blood (10). The reliability of
extrapolating neuronal genotypes from peripheral
blood or lymphocytes remains to be determined.
In the future, comparisons between multiple tissues
will be important for understanding the mecha-
nism and extent of somatic variation in repeat
length. Somatic variation may be an important fac-
tor in the clinical heterogeneity in FTD–ALS fami-
lies, where longer expansions in motor neurons
might lead to ALS, whereas expansion in cortical
neurons might result in FTD. Similarly, the length
of the expanded trinucleotide repeat in the muscle
of patients with myotonic dystrophy can be consid-
erably longer than in blood or lymphoblastoid cells
(21).
The minimal C9ORF72 expansion required for
pathogenicity is not known, and the penetrance of
disease in individuals carrying expanded alleles
remains to be determined (3). One study (5)
reported a 50% likelihood of disease manifestation
by age 57 and almost 100% by age 80. Few studies
have examined the transmission of expanded
C9ORF72alleles (8). Earlier onset in later genera-
tions of families with the C9ORF72 expansion has
been described (2, 21). RNA-mediated pathology
is suggested by a dependence on repeat length, but
reduced RNA expression from the expanded allele
has also been described (2). Further studies will be
needed to determine the relative contributions of
repeat length to RNA toxicity, protein toxicity,
and reduced gene expression.
Our ﬁndings suggest a possible etiological rela-
tionship between the C9ORF72 expansion and dis-
ease progression from bipolar disorder to FTD.
The aﬀected parent has a history of lifetime tem-
peramental instability reminiscent of the bipolar
spectrum (14) and was hospitalized with incapaci-
tating manic features in the seventh decade of life.
The oﬀspring with the larger average repeat expan-
sion developed bipolar disorder in the third dec-
ade. In the future, it will be of great interest to
examine C9ORF72 in two-generation families with
bipolar disorder with or without dementia, in those
with atypical cognitive and personality proﬁles,
and in families with other neuropsychiatric syn-
dromes demonstrating clinical anticipation. This
approach may provide an insight into the variety
of symptoms within the bipolar spectrum of dis-
ease, including intergenerational variability of clin-
ical phenomena (14). The C9ORF72 expansion
could also have an impact on early brain develop-
ment, as suggested for the trinucleotide repeat in
Huntington’s disease (22). Screening by PCR can
detect the repeat expansion, but Southern blots
will be required to demonstrate genetic anticipa-
tion and determine the relationship between repeat
length and clinical presentation. The frequency of
the C9ORF72 expansion in our bipolar disorder
cohort was approximately 1%, indicating that this
is unlikely to be a common cause of bipolar dis-
ease. Analysis of larger cohorts of aﬀected individ-
uals will be needed to better deﬁne the
contribution of the C9ORF72 repeat expansions to
bipolar disorder.
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